Skip to main content
Top
Published in: Journal of General Internal Medicine 5/2007

01-05-2007 | Original Article

What’s in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice

Authors: Michael A. Steinman, MD, Mary-Margaret Chren, MD, C. Seth Landefeld, MD

Published in: Journal of General Internal Medicine | Issue 5/2007

Login to get access

Background

The use of brand rather than generic names for medications can increase health care costs. However, little is known at a national level about how often physicians refer to drugs using their brand or generic names.

Objective

To evaluate how often physicians refer to drugs using brand or generic terminology.

Design and Participants

We used data from the 2003 National Ambulatory Medical Care Survey (NAMCS), a nationally representative survey of 25,288 community-based outpatient visits in the United States. After each visit, patient medications were recorded on a survey encounter form by the treating physician or transcribed from office notes.

Measurements

Our main outcome measure was the frequency with which medications were recorded on the encounter form using their brand or generic names.

Results

For 20 commonly used drugs, the median frequency of brand name use was 98% (interquartile range, 81–100%). Among 12 medications with no generic competition at the time of the survey, the median frequency of brand name use was 100% (range 92–100%). Among 8 medications with generic competition at the time of the survey (“multisource” drugs), the median frequency of brand name use was 79% (range 0–98%; P < .001 for difference between drugs with and without generic competition).

Conclusions

Physicians refer to most medications by their brand names, including drugs with generic formulations. This may lead to higher health care costs by promoting the use of brand-name products when generic alternatives are available.
Literature
1.
go back to reference Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med. 2005;142:891–7.PubMed Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med. 2005;142:891–7.PubMed
2.
go back to reference Banahan BF, 3rd, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080–8.PubMedCrossRef Banahan BF, 3rd, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080–8.PubMedCrossRef
3.
go back to reference Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662–74.PubMedCrossRef Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662–74.PubMedCrossRef
4.
7.
go back to reference Mathews AW. When a drug maker creates a new pill, Uncle Sam vets name. FDA tries to avoid mix-ups, similar monikers, dupes; Bonviva becomes Boniva. Wall Street J. March 17, 2006:1. Mathews AW. When a drug maker creates a new pill, Uncle Sam vets name. FDA tries to avoid mix-ups, similar monikers, dupes; Bonviva becomes Boniva. Wall Street J. March 17, 2006:1.
8.
go back to reference Hemminki E, Enlund H, Hellevuo K, Laurila R, Turakka H. Trade names and generic names. Problems for prescribing physicians. Scand J Prim Health Care. 1984;2:84–7.PubMed Hemminki E, Enlund H, Hellevuo K, Laurila R, Turakka H. Trade names and generic names. Problems for prescribing physicians. Scand J Prim Health Care. 1984;2:84–7.PubMed
9.
go back to reference Bower AD, Burkett GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract. 1987;24:612–6.PubMed Bower AD, Burkett GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract. 1987;24:612–6.PubMed
11.
go back to reference Caves R, Hurwitz M. Persuasion or information: promotion and the shares of brand name and generic pharmaceuticals. J Law Econ. 1988;31:299–320.CrossRef Caves R, Hurwitz M. Persuasion or information: promotion and the shares of brand name and generic pharmaceuticals. J Law Econ. 1988;31:299–320.CrossRef
12.
go back to reference Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25:2875–90.PubMedCrossRef Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25:2875–90.PubMedCrossRef
13.
14.
go back to reference Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13:207–14.PubMedCrossRef Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13:207–14.PubMedCrossRef
15.
go back to reference Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051–63.PubMedCrossRef Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051–63.PubMedCrossRef
18.
19.
go back to reference Schwab M, Oetzel C, Morike K, Jagle C, Gleiter CH, Eichelbaum M. Using trade names: a risk factor for accidental drug overdose. Arch Intern Med. 2002;162:1065–6.PubMedCrossRef Schwab M, Oetzel C, Morike K, Jagle C, Gleiter CH, Eichelbaum M. Using trade names: a risk factor for accidental drug overdose. Arch Intern Med. 2002;162:1065–6.PubMedCrossRef
Metadata
Title
What’s in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice
Authors
Michael A. Steinman, MD
Mary-Margaret Chren, MD
C. Seth Landefeld, MD
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 5/2007
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-006-0074-3

Other articles of this Issue 5/2007

Journal of General Internal Medicine 5/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.